{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Status:
Investigational
Source:
NCT01234506: Phase 2 Interventional Completed Oxidative Stress
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Secoisolariciresinol diglucoside (SDG) isolated from flaxseed is a lipid-lowering and antioxidant agent. It suppresses the development of hypercholesterolemic atherosclerosis in rabbits. Secoisolariciresinol diglucoside has been shown to have antioxidant and cardioprotective properties. SDG interferes with the development of different types of
diseases like cardiovascular, diabetic, lupus nephritis, bone, kidney, menopause, reproduction, mental stress,
immunity, atherosclerosis, hemopoietic, liver necrosis and urinary disorders due to its various biological properties
including anti-inflammatory, antioxidant, antimutagenic, antimicrobial, antiobesity, antihypolipidemic and
neuroprotective effects. Moreover, SDG has a defending mediator against various cancers by modulating multiple
cell signaling pathways. The animal and human studies have shown the prevention
role of SDG against some cancers (breast, lung and
colon) as a result of its strong anti-proliferative, antioxidant,
anti-oestrogenic and/or anti-angiogenic activity. It
is proposed that the anticancer activity of SDG is associated
with the inhibition of enzymes involved in carcinogenesis. Human studies showed the SDG as potential
cardiovascular protector by mediating the mechanisms
of total cholesterol, LDL-cholesterol, HDL-cholesterol,
triacylglycerides and glucose metabolism. It was observed
that 20 hypercholesterolaemia and hypertriglyceridaemia
subjects receiving 600 mg SDG per day for
8 weeks led to significant reductions in total cholesterol,
LDL-cholesterol and glucose concentrations compared
with the placebo group. The animal and human studies revealed
that high fat diet containing 0 · 5 to 1 · 0 % SDG reduces
liver triglycerides content, serum triglycerides, total
cholesterol, and insulin and leptin concentrations that
resulted in significantly reduced visceral fat gain as compared
to group of mice receiving high fat diet without
SDG. SDG reduces C-reactive protein concentrations
which are associated with insulin resistance and diabetes
mellitus in type 2 diabetics. Daily consumption of
low-fat muffin enriched with SDG (500 mg/day) for
6 week can reduce CRP concentrations. SDG has
long acting hypotensive effect mediated through the guanylate
cyclase enzyme.
Status:
Investigational
Source:
NCT03427268: Phase 2 Interventional Completed Advanced Colorectal Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PM-060184 is a new type of marine polyketide isolated from the Madagascan sponge. PM060184 belongs to a new family of tubulin-binding agents. PM060184 is an inhibitor of tubulin polymerization that reduces microtubule dynamicity in cells by 59%. Interestingly, PM060184 suppresses microtubule shortening and growing at a similar extent. PM060184 is able to overcome P-gp mediated resistance in vivo, an effect that could be related to its high binding affinity for tubulin. PM-060184 demonstrated antimitotic properties in human tumor cells lines at subnanomolar concentrations and display a distinct inhibition mechanism on microtubules. An antivascular mechanism is contributing to the antitumor activities of plocabulin. PM-060184 I in phase II clinical trial for the treatment of breast and colorectal cancer.
Status:
Investigational
Source:
NCT04668235: Phase 3 Interventional Completed COVID-19
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01725139: Phase 1 Interventional Completed Idiopathic Pulmonary Fibrosis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Omipalisib, also known as GSK2126458, is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib (GSK2126458, GSK458) is a highly selective and potent inhibitor of p110α/β/δ/γ, mTORC1/2 with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM in cell-free assays, respectively. It is also a low picomolar inhibitor of the common activating
mutants of p110a (E542K, E545K, and H1047R) found in
human cancer. Omipalisib (GSK2126458) binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival. GlaxoSmithKline (GSK) is developing omipalisib, a phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor as well as mTOR complex 1 and 2 inhibitor, for the potential oral treatment of cancer and idiopathic pulmonary fibrosis.
Status:
Investigational
Source:
NCT01225939: Phase 1 Interventional Completed Type 2 Diabetes Mellitus
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03313297: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
AZD4017, a 11β-hydroxysteroid dehydrogenase type 1 inhibitor, has been developed by AstraZeneca for the treatment of obesity, raised intraocular pressure (IOP) and type 2 diabetes. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. However, studies were discontinued due to safety and efficacy reasons. Besides, specific inhibition of 11β-HSD1 can decrease intracranial pressure and consequently treat patients with Idiopathic Intracranial Hypertension (IIH), thus AZD4017 participated in phase II clinical trials to treat this disease. IIH, also known as benign intracranial hypertension or pseudotumor cerebri, is a condition of unknown etiology characterized by elevated intracranial pressure (ICP) and papilledema. In addition, AZD4017 in combination with prednisolone participated in phase II clinical trials for patients with Iatrogenic Cushing's Disease. It was postulated that the adverse metabolic effects of prednisolone could be reduced by co-administration of AZD4017.
Status:
Investigational
Source:
NCT01652742: Phase 1 Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03725722: Phase 2 Interventional Completed Atopic Dermatitis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:emestedastat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
